

HOUSE COMMITTEE OF REFERENCE REPORT

Chair of Committee

April 25, 2023
Date

Committee on Public & Behavioral Health & Human Services.

After consideration on the merits, the Committee recommends the following:

SB23-195 be amended as follows, and as so amended, be referred to the Committee on Appropriations with favorable recommendation:

1 Amend reengrossed bill, page 4, strike line 9 and substitute "EQUIVALENT
2 OR, FOR A PRESCRIPTION DRUG THAT IS A BIOLOGICAL PRODUCT, THE
3 PRESCRIPTION DRUG DOES NOT HAVE A BIOSIMILAR DRUG, AS DEFINED IN
4 42 U.S.C. SEC. 262 (i)(2), OR AN INTERCHANGEABLE BIOLOGICAL
5 PRODUCT, AS DEFINED IN 42 U.S.C. SEC. 262 (i)(3); OR".

6 Page 4, line 10, after "EQUIVALENT," insert "A BIOSIMILAR DRUG, OR AN
7 INTERCHANGEABLE BIOLOGICAL PRODUCT,".

8 Page 4, strike lines 20 through 27.

9 Page 5, strike lines 1 and 2 and substitute:

10 "(b) A COVERED PERSON IS NOT REQUIRED TO COMPLY WITH THE
11 UTILIZATION MANAGEMENT PROCESSES DESCRIBED IN SUBSECTION
12 (1)(a)(II) OF THIS SECTION, INCLUDING PRIOR AUTHORIZATION AND
13 STEP-THERAPY PROTOCOL REQUIREMENTS, WHEN THOSE PROCESSES ARE
14 PROHIBITED UNDER THIS ARTICLE 16 OR OTHER APPLICABLE STATE LAW."

15 Page 5, strike lines 16 through 21 and substitute:

16 "(4) AS USED IN THIS SECTION, "COST-SHARING REQUIREMENT"
17 MEANS ANY COPAYMENT,".